Page 25 - கடுமையான முதலீட்டாளர் உறவுகள் இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
4D pharma plc: 4D Pharma Announces U S SEC Declares Registration Statement Effective with Respect to the Issuance of 4D Pharma American Depositary Shares on NASDAQ
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Fulcrum Therapeutics Recognizes Rare Disease Day 2021 Theme of global unity highlights critical role of building communities of support for patients and families affected by rare diseases around the world
February 26, 2021 07:00 ET | Source: Fulcrum Therapeutics Fulcrum Therapeutics
CAMBRIDGE, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE)
Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the company’s recognition of Rare Disease Day 2021.
“While COVID-19 has had an impact on most people around the world, it has put a new spotlight on the importance of connectivity and community for people affected by rare diseases who are at a higher risk of feelings of isolation and can face significant challenges in accessing information and healthcare services,” said Robert J. Gould, Ph.D., Fulcrum’s presiden
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Scout Bio to Present at the BofA Securities 2021 Animal Health Summit
Scout BioFebruary 18, 2021 GMT
PHILADELPHIA, Feb. 18, 2021 (GLOBE NEWSWIRE) Scout Bio, a biotechnology company revolutionizing pet medicine by delivering a pipeline of one-time gene therapies for major chronic pet health conditions, today announced that Mark Heffernan, Scout Bio’s Chief Executive Officer, will present at the upcoming BofA Securities 2021 Animal Health Summit on Thursday, February 25, 2021 at 2:35 p.m. ET.
About Scout Bio Scout Bio is a biotechnology company revolutionizing pet medicine by delivering a pipeline of one-time gene therapies for major chronic pet health conditions. Scout Bio’s therapeutics are designed to induce long-term expression of therapeutic proteins in pet patients using AAV vector technology. Scout Bio has a research and development collaboration with the University of P
Ayala Pharmaceuticals Announces $25 Million Strategic Financing
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Passage Bio Appoints Maxine Gowen, Ph.D. to Board of Directors
Passage BioFebruary 19, 2021 GMT
PHILADELPHIA, Feb. 19, 2021 (GLOBE NEWSWIRE) Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (CNS) disorders, today announced the appointment of Maxine Gowen, Ph.D., to its board of directors, effective Feb. 18. Dr. Gowen is chief executive officer of Tamuro Bio, a post that she has held since July 2019.
“We are immensely excited to have Maxine join our board of directors,” said Dr. Bruce Goldsmith, president and chief executive officer of Passage Bio. “Her public company leadership and deep clinical development expertise will provide tremendous support to Passage Bio as we transition to a clinical development organization in the first half of 2021.”
vimarsana © 2020. All Rights Reserved.